GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cynosure Inc (NAS:CYNO) » Definitions » Cash, Cash Equivalents, Marketable Securities

Cynosure (Cynosure) Cash, Cash Equivalents, Marketable Securities : $200.2 Mil (As of Dec. 2016)


View and export this data going back to 2005. Start your Free Trial

What is Cynosure Cash, Cash Equivalents, Marketable Securities?

Cynosure's quarterly cash, cash equivalents, marketable securities increased from Jun. 2016 ($170.41 Mil) to Sep. 2016 ($172.10 Mil) and increased from Sep. 2016 ($172.10 Mil) to Dec. 2016 ($200.16 Mil).

Cynosure's annual cash, cash equivalents, marketable securities increased from Dec. 2014 ($107.19 Mil) to Dec. 2015 ($144.00 Mil) and increased from Dec. 2015 ($144.00 Mil) to Dec. 2016 ($200.16 Mil).


Cynosure Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Cynosure's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynosure Cash, Cash Equivalents, Marketable Securities Chart

Cynosure Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 126.67 120.29 107.19 144.00 200.16

Cynosure Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 144.00 139.93 170.41 172.10 200.16

Cynosure Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Cynosure  (NAS:CYNO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Cynosure Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Cynosure's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynosure (Cynosure) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cynosure Inc (NAS:CYNO) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
Executives
Thomas H Robinson director C/O CYNOSURE, INC., 5 CARISLE ROAD, WESTFORD MA 01886
Marina Hatsopoulos director 39 MANNING ROAD, BILLERICA MA 01821
George J Vojta director 340 PONDFFIELD ROAD, BROXVILLE NY 10708

Cynosure (Cynosure) Headlines

From GuruFocus

Cynosure: A Value Play on Vanity

By guruek Mike Havrilla 01-19-2009

Small Caps: Assessing Management Guidance and Analysts' Estimates

By Robert Abbott Robert Abbott 11-05-2018

Steven Cohen Invests in Cynosure

By David Goodloe David Goodloe 04-26-2016